Explore

Trendline Trendline
Ono Pharma Presents Promising Phase 2 Data for ONO-2808 in Multiple System Atrophy

Ono Pharma Presents Promising Phase 2 Data for ONO-2808 in Multiple System Atrophy

Ono Pharma Presents Promising Phase 2 Data for ONO-2808 in Multiple System Atrophy
Trendline Trendline
Bristol Myers Squibb to Engage in Goldman Sachs Global Healthcare Conference

Bristol Myers Squibb to Engage in Goldman Sachs Global Healthcare Conference

Bristol Myers Squibb to Engage in Goldman Sachs Global Healthcare Conference
Trendline Trendline
FDA Initiates Priority Review for Sanofi's Gaucher Disease Drug Venglustat

FDA Initiates Priority Review for Sanofi's Gaucher Disease Drug Venglustat

FDA Initiates Priority Review for Sanofi's Gaucher Disease Drug Venglustat
Trendline Trendline
GLP-1 Therapies Transforming Metabolic Disease Treatment Landscape

GLP-1 Therapies Transforming Metabolic Disease Treatment Landscape

GLP-1 Therapies Transforming Metabolic Disease Treatment Landscape
Reuters Reuters
CVS brings back coverage for Lilly's obesity drug Zepbound

CVS brings back coverage for Lilly's obesity drug Zepbound

May 28 (Reuters) - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option for insurance coverage.
Trendline Trendline
Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval
Rapid Read Rapid Read
Global Grants for Gut Health Initiative Opens 2026 Funding Cycle for Microbiome Research

Global Grants for Gut Health Initiative Opens 2026 Funding Cycle for Microbiome Research

The Global Grants for Gut Health, a collaboration between Yakult and Nature Portfolio, has launched its 2026 funding cycle to support research on the gut microbiota's impact on neurological function. This initiative aims to fund innovative projects that explore the gut-brain axis, including mechanisms like immune signaling and neurotransmission. Up to three grantees will receive $100,000 each to advance their research. The application period is open until July 14, 2026, with winners to be announced in December 2026. The program seeks candidates with a strong track record in their fields who can lead independent, interdisciplinary research projects.
Rapid Read Rapid Read
VA Launches Clinical Trial for MDMA-Assisted Therapy for Veterans

VA Launches Clinical Trial for MDMA-Assisted Therapy for Veterans

The U.S. Department of Veterans Affairs (VA) has initiated a clinical trial to evaluate the effectiveness of MDMA-assisted therapy for veterans suffering from severe mental health conditions, including PTSD and alcoholism. This trial represents a significant federal effort to explore psychedelic-assisted treatments as potential solutions for rising rates of trauma, addiction, and suicide among veterans. The study will involve around 80 veterans at VA facilities in Rhode Island and Connecticut, comparing MDMA-assisted therapy with traditional psychotherapy paired with a placebo. The trial aims to assess the safety and efficacy of this innovative treatment approach.
Rapid Read Rapid Read
Stallergenes Greer Foundation Awards €100,000 to Innovators in Allergy Research

Stallergenes Greer Foundation Awards €100,000 to Innovators in Allergy Research

The Stallergenes Greer Foundation has announced the recipients of its 2025 Science Awards for Allergy, recognizing significant contributions to allergy research and patient engagement. The awards, totaling €100,000, were distributed among four researchers who excelled in two categories: Innovation in Treatment and Patient Commitment. The recipients include Assoc. Professor Alexander Eggel from the University of Bern, Dr. Janice A. Layhadi from Imperial College London, Dr. Laurent Reber from Inserm, and Dr. Pablo Rodríguez del Río from Hospital Infantil Universitario Niño Jesús. Their research spans from improving diagnostic and therapeutic options for allergic patients to developing allergen-specific mRNA vaccines and understanding patient perspectives in food immunotherapy.
Trendline Trendline
Arrowhead Pharmaceuticals Reveals Positive Data on Plozasiran for Patients with Renal and Hepatic Impairments

Arrowhead Pharmaceuticals Reveals Positive Data on Plozasiran for Patients with Renal and Hepatic Impairments

Arrowhead Pharmaceuticals Reveals Positive Data on Plozasiran for Patients with Renal and Hepatic Impairments
Rapid Read Rapid Read
UMass Chan Receives $1.6M Grant for Safer Gene Therapy Delivery Research

UMass Chan Receives $1.6M Grant for Safer Gene Therapy Delivery Research

UMass Chan Medical School has been awarded a $1.6 million grant from the National Institute of General Medical Sciences to enhance the safety of gene therapy delivery methods. The research, led by Phillip Tai, focuses on improving adeno-associated viral vectors, which are commonly used in gene therapy to deliver genetic material into cells. The study aims to reduce the potential risks associated with these vectors, such as the inadvertent integration of genetic material into a patient's DNA, which could lead to cancer.
Trendline Trendline
Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad